Some rich people think that a company called Iovance Biotherapeutics is going down in value soon, so they are betting money on it. This is different from normal because usually, only small investors do this. Some experts still think the company is good and will go up in value. Options trading is a way to make more money but also has more risk. People who do it need to be careful and learn a lot about it. Read from source...

- The title is misleading and sensationalized, implying that there are some hidden or urgent trends in options trading for Iovance Biotherapeutics, while the article only provides a vague overview of recent options activity.
- The article relies on unverified sources and anecdotal evidence to support its claims, such as "we noticed this today" and "somebody knows something is about to happen". These statements lack credibility and transparency, and do not provide any concrete data or analysis to back them up.
- The article contradicts itself by presenting different ratings from various analysts, some of which are outdated or inconsistent with the current market situation. For example, Goldman Sachs has a Buy rating for Iovance Biotherapeutics at $19, while CharAI Capital has a Buy rating at $34. This shows a lack of consistency and clarity in the research and opinion of these experts, and undermines their credibility as reliable sources of information.
- The article uses emotional language and appeals to fear and greed, such as "bearish stance", "wealthy individuals", "should know", "split between 47% bullish and 52%, bearish". This tone is unprofessional and manipulative, and does not encourage rational decision-making or informed investment choices.
- The article fails to provide any actionable insights or strategies for traders who want to learn from the options trends in Iovance Biotherapeutics. Instead, it only repeats common pitfalls and risks associated with trading options, without offering any solutions or guidance on how to mitigate them. This leaves the readers feeling frustrated and uninformed, rather than empowered and knowledgeable.

The overall sentiment of these big-money traders is split between 47% bullish and 52%, bearish.

1. Buy IOVA Jan 20 2025 $34 call option at a premium of $6 per contract. This option has a delta of 0.67, meaning it is slightly in the money and will gain value as IOVA rises above $33.63. The potential profit is limited to the difference between the strike price and the current stock price, or $1 per contract. The risk is limited to the premium paid, or $6 per contract. This option is suitable for investors who expect a significant upside in IOVA within the next two years and are willing to pay a relatively high premium for it.

2. Sell IOVA Mar 18 2024 $15 put option at a premium of $3 per contract. This option has a delta of -0.69, meaning it is slightly out of the money and will lose value as IOVA falls below $18.61. The potential profit is limited to the premium received, or $3 per contract. The risk is unlimited, as the holder of this option is obligated to buy IOVA at $15 per share if it goes below that level. This option is suitable for investors who expect a moderate downside in IOVA within the next few months and are willing to collect a relatively high premium for it.

3. Buy IOVA Mar 18 2024 $12.5 call option at a premium of $1 per contract. This option has a delta of 0.37, meaning it is slightly out of the money and will gain value as IOVA rises above $13.63. The potential profit is limited to the difference between the strike price and the current stock price, or $3.5 per contract. The risk is limited to the premium paid, or $1 per contract. This option is suitable for investors who expect a moderate upside in IOVA within the next few months and are willing to pay a relatively low premium for it.